Skip to content
Markets News
Earnings2 min read

PureTech Sees Cash Burn Falling as Portfolio Funding Shifts

Makkler Newsroom
September 23, 2026 · Based on reporting by MarketBeat

The biotech reported a first-half profit driven by investment gains and said its lower-cost model should extend its cash runway through 2028.

PureTech Health said it expects annual cash burn of $30 million to $40 million as more late-stage drug development moves to separately funded companies. It ended June with $220 million in cash and short-term investments at the parent level, which management said supports operations through at least the end of 2028.

The company reported $67.2 million in first-half profit, compared with a $44.6 million loss a year earlier. The swing was mainly accounting gains, including a $120.4 million increase in the value of its Seaport Therapeutics investment after Seaport’s Nasdaq listing.

That profit did not come from strong sales. Revenue rose 92% to $3.6 million, largely from royalties tied to Cobenfy, the schizophrenia drug marketed by Bristol Myers Squibb. Operating expenses increased to $55.9 million from $49.8 million, as research and development spending rose.

On the September 22 results call, Chief Executive Robert Lyne said the expected annual cash burn compares with about $90 million when PureTech ran more late-stage programs itself. The forecast includes overhead and innovation spending, and reflects its strategy of advancing early research before raising outside capital for later development.

Seaport raised about $260 million in its May IPO. PureTech held a 31.2% stake, valued at roughly $360 million on September 18, while retaining potential royalties and milestone payments.

Another portfolio company, Celea Therapeutics, raised $180 million in July and began a Phase 3 trial of deupirfenidone for idiopathic pulmonary fibrosis. PureTech contributed $30 million to that financing and reserved a further $70 million for possible investment. Its cash figure at June 30 excludes $17.5 million of the contribution paid after the half-year.

Gallop Oncology’s next step depends on new funding. It plans to seek external capital by the first half of 2027 before starting a Phase 2 trial of LYT-200 in high-risk myelodysplastic syndromes. The FDA granted the drug Fast Track status in September.

Topics
PRTCSPTXBMYCelea TherapeuticsGallop OncologyCobenfy
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.